Home › Myelodysplastic Syndromes › Ohio › Columbus
Myelodysplastic Syndromes clinical trials in Columbus, OH
14 studies for Myelodysplastic Syndromes are looking for participants at sites in and around Columbus (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
HPC Offered for PRESERVE Expansion
RecruitingObservational study
- The Ohio State University Medical Center, Columbus
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
RecruitingPhase 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Ohio State University Comprehensive Cancer Center, Columbus
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Collection of Tissue Samples for Cancer Research
RecruitingObservational study
- Ohio State University, Columbus
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RecruitingPhase 1/2
- The Ohio State University, Columbus
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
RecruitingPhase 1
- Ohio State University, The James Comprehensive Cancer, Columbus
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RecruitingPhase 2/3
- Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
RecruitingPhase 3
- Ohio State University Comprehensive Cancer Center, Columbus
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
- Nationwide Children's Hospital, Columbus
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
RecruitingPhase 1
- Ohio State University Medical Center, Columbus
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RecruitingPhase 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Columbus
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
RecruitingPhase 1
- The Ohio State University Wexner Medical Center - James Cancer Hosp, Columbus
About Myelodysplastic Syndromes
Myelodysplastic Syndromes (MDS) are rare. They are sometimes found during a routine blood test. Learn symptoms, risk factors, and treatment options.
More about Myelodysplastic Syndromes on MedlinePlus
Myelodysplastic Syndromes trials in other cities
- Houston, TX43 studies
- Baldwin Park, CA27 studies
- New York City, NY22 studies
- Seattle, WA21 studies
- Boston, MA20 studies
- Tampa, FL20 studies
- Washington, DC19 studies
- Miami, FL17 studies
- Durham, NC14 studies
- Atlanta, GA13 studies
- Chicago, IL13 studies
- St. Louis, MO13 studies
Other studies in Columbus
- Non-Small Cell Lung Cancer57 studies
- Cancer (all types)40 studies
- Breast Cancer39 studies
- Ovarian Cancer39 studies
- Lung Cancer36 studies
- Acute Myeloid Leukemia34 studies
- Chronic Lymphocytic Leukemia29 studies
- Metastatic Cancer25 studies
- Multiple Myeloma25 studies
- Prostate Cancer25 studies
- Endometrial Cancer24 studies
- Colorectal Cancer24 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.